Advances in Anaplastic Thyroid Cancer Treatment.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
환자: the sense of nihilism and hopelessness characteristic of the approach used in past decades
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
Surgical resection of the primary tumor after neoadjuvant approach, regardless of stage, should be the goal in most patients with BRAF-mutated ATC to decrease locoregional complications, improve quality of life, and prolong survival. Combination therapy with kinase inhibitors plus immune checkpoint inhibitors is the preferred treatment regimen in patients with metastatic ATC.
In 2025, it is no longer appropriate to view anaplastic thyroid cancer (ATC) patients with the sense of nihilism and hopelessness characteristic of the approach used in past decades.
APA
Hamidi S, Maniakas A, Cabanillas ME (2025). Advances in Anaplastic Thyroid Cancer Treatment.. Endocrinology and metabolism clinics of North America, 54(3), 361-375. https://doi.org/10.1016/j.ecl.2025.03.009
MLA
Hamidi S, et al.. "Advances in Anaplastic Thyroid Cancer Treatment.." Endocrinology and metabolism clinics of North America, vol. 54, no. 3, 2025, pp. 361-375.
PMID
40716892
Abstract
In 2025, it is no longer appropriate to view anaplastic thyroid cancer (ATC) patients with the sense of nihilism and hopelessness characteristic of the approach used in past decades. Early, rapid somatic genomic testing to determine BRAF (v-raf murine sarcoma viral oncogene homolog B1) status is critical for the optimal management of ATC. Surgical resection of the primary tumor after neoadjuvant approach, regardless of stage, should be the goal in most patients with BRAF-mutated ATC to decrease locoregional complications, improve quality of life, and prolong survival. Combination therapy with kinase inhibitors plus immune checkpoint inhibitors is the preferred treatment regimen in patients with metastatic ATC.
MeSH Terms
Humans; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Proto-Oncogene Proteins B-raf; Protein Kinase Inhibitors
같은 제1저자의 인용 많은 논문 (5)
- Real-World Experience with Lenvatinib plus Pembrolizumab in Metastatic Wild-Type Anaplastic Thyroid Carcinoma.
- Characterization of Advanced RAS-driven Follicular-derived Thyroid Cancers and Review of Future Therapeutic Avenues.
- Circulating Tumor DNA as a Biomarker for Disease Surveillance in Anaplastic Thyroid Cancer.
- Recurrent Poorly Differentiated Thyroid Cancer Successfully Treated With Radiation and Immunotherapy.
- Initial Management of BRAF V600E-Variant Anaplastic Thyroid Cancer: The FAST Multidisciplinary Group Consensus Statement.